Literature DB >> 9512127

Human gallbladder mucosal function: effects on intraluminal fluid and lipid composition in health and disease.

S Ginanni Corradini1, G Yamashita, H Nuutinen, A Chernosky, C Williams, L Hays, M L Shiffman, R M Walsh, J Svanvik, P Della Guardia, L Capocaccia, R T Holzbach.   

Abstract

Gallbladder mucosal absorption of fluid during fasting is a well-known process. Indirect in vivo and recent in vitro evidence for physiologically relevant gallbladder absorption of cholesterol and phospholipids from bile has been observed in humans. The present study explored and compared by indirect means the relative efficiences of human gallbladder mucosal absorption of fluid and lipids in health and disease. Biliary lipids and pigment content were measured in fasting gallbladder bile samples obtained from gallstone-free controls and from four study groups: multiple and solitary cholesterol gallstone patients, and morbidly obese subjects with and without gallstones. Bile salts and pigment content were significantly greater in gallstone-free controls than in all other disease study groups. This was interpreted as evidence of more effective gallbladder mucosal fluid absorption in nonobese gallstone-free controls compared to that in all other groups. Correlation plot analyses of biliary lipids showed lower concentrations of phospholipids than expected from the index bile salt concentrations. The same was found for cholesterol concentrations but only in supersaturated samples. These findings were much more pronounced in gallstone free-controls and were accordingly interpreted as evidence of more efficient gallbladder absorption of both phospholipids and cholesterol in controls compared with that found in each of the disease study groups. Moreover, impaired gallbladder mucosal function, while invariably associated with cholesterol gallstone disease, was not found to be a necessary consequence of the physical presence of stones. It is concluded that efficient gallbladder mucosal absorption of both fluid and apolar lipids from bile is a normal physiological process that is often seriously impaired in the presence of either cholesterol gallstone disease or at least one of its precursor forms.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9512127     DOI: 10.1023/a:1018858406560

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  31 in total

1.  Effect of dietary cholesterol on phosphatidylcholines and phosphatidylethanolamines in bile and gallbladder mucosa in the prairie dog.

Authors:  M L Booker; T E Scott; W W La Morte
Journal:  Gastroenterology       Date:  1989-11       Impact factor: 22.682

2.  Bidirectional transport of cholesterol between gallbladder epithelial cells and model bile.

Authors:  A Hayashi; S P Lee
Journal:  Am J Physiol       Date:  1996-09

3.  High protein and total lipid concentration are associated with reduced metastability of bile in an early stage of cholesterol gallstone formation.

Authors:  S M Strasberg; J L Toth; S Gallinger; P R Harvey
Journal:  Gastroenterology       Date:  1990-03       Impact factor: 22.682

4.  Hepatic secretion of bilirubin and biliary lipids in patients with alcoholic cirrhosis of the liver.

Authors:  R Raedsch; A Stiehl; U Gundert-Remy; S Walker; A Sieg; P Czygan; B Kommerell
Journal:  Digestion       Date:  1983       Impact factor: 3.216

5.  Effects of acute changes of bile acid pool composition on biliary lipid secretion.

Authors:  N Carulli; P Loria; M Bertolotti; M Ponz de Leon; D Menozzi; G Medici; I Piccagli
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

6.  Enzymatic measurement of choline-containing phospholipids in bile.

Authors:  D Gurantz; M F Laker; A F Hofmann
Journal:  J Lipid Res       Date:  1981-02       Impact factor: 5.922

7.  High vesicular cholesterol and protein in bile are associated with formation of cholesterol but not pigment gallstones.

Authors:  K Chijiiwa; I Hirota; H Noshiro
Journal:  Dig Dis Sci       Date:  1993-01       Impact factor: 3.199

8.  Mucin in gall bladder bile of gall stone patients: influence of treatment with chenodeoxycholic acid and ursodeoxycholic acid.

Authors:  S Sahlin; A Danielsson; B Angelin; E Reihnér; R Henriksson; K Einarsson
Journal:  Gut       Date:  1988-11       Impact factor: 23.059

9.  Nucleation time: a key factor in the pathogenesis of cholesterol gallstone disease.

Authors:  K R Holan; R T Holzbach; R E Hermann; A M Cooperman; W J Claffey
Journal:  Gastroenterology       Date:  1979-10       Impact factor: 22.682

10.  Reduced cholesterol metastability of hepatic bile and its further decline in gall bladder bile in patients with cholesterol gall stones.

Authors:  K Nakano; K Chijiiwa
Journal:  Gut       Date:  1993-05       Impact factor: 23.059

View more
  5 in total

Review 1.  Cholesterol gallstone disease: focusing on the role of gallbladder.

Authors:  Yongsheng Chen; Jing Kong; Shuodong Wu
Journal:  Lab Invest       Date:  2014-12-15       Impact factor: 5.662

2.  Biliary alpha 1-acid glycoprotein concentrations in gallstone-free controls and in patients with multiple or solitary cholesterol gallstones.

Authors:  H Nuutinen; M Abei; J Schwarzendrube; S Ginanni Corradini; R M Walsh; P Kawczak; R T Holzbach
Journal:  Dig Dis Sci       Date:  1995-08       Impact factor: 3.199

3.  Expression and regulation of scavenger receptor class B type I (SR-BI) in gall bladder epithelium.

Authors:  J F Miquel; M Moreno; L Amigo; H Molina; P Mardones; I I Wistuba; A Rigotti
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

Review 4.  An Update on the Lithogenic Mechanisms of Cholecystokinin a Receptor (CCKAR), an Important Gallstone Gene for Lith13.

Authors:  Helen H Wang; Piero Portincasa; Min Liu; Patrick Tso; David Q-H Wang
Journal:  Genes (Basel)       Date:  2020-11-29       Impact factor: 4.096

5.  The Risk of Colorectal Neoplasia in Patients with Gallbladder Diseases.

Authors:  Sung Noh Hong; Tae Yoon Lee; Sung-Cheol Yun
Journal:  J Korean Med Sci       Date:  2015-08-13       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.